BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

889 related articles for article (PubMed ID: 12447513)

  • 21. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli.
    Wu UI; Yang CS; Chen WC; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2010 Aug; 43(4):310-6. PubMed ID: 20688291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
    Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
    P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Bacteremia caused by Escherichia coli and Klebsiella pneumoniae producing extended-spectrum betalactamases: mortality and readmission-related factors].
    Perianes-Díaz ME; Novo-Veleiro I; Solís-Díaz K; Prolo-Acosta A; García-García I; Alonso-Claudio G
    Med Clin (Barc); 2014 May; 142(9):381-6. PubMed ID: 23735867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and antimicrobial resistance patterns of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated from blood cultures in an Istanbul University Hospital.
    Koksal F; Ak K; Kucukbasmaci O; Samasti M
    Chemotherapy; 2009; 55(4):293-7. PubMed ID: 19521075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia.
    Martínez JA; Aguilar J; Almela M; Marco F; Soriano A; López F; Balasso V; Pozo L; Mensa J
    J Antimicrob Chemother; 2006 Nov; 58(5):1082-5. PubMed ID: 16950822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome.
    Kim SH; Kwon JC; Choi SM; Lee DG; Park SH; Choi JH; Yoo JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
    Ann Hematol; 2013 Apr; 92(4):533-41. PubMed ID: 23161391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Labombardi VJ; Rojtman A; Tran K
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):313-5. PubMed ID: 17084784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.
    Shanthi M; Sekar U
    J Assoc Physicians India; 2010 Dec; 58 Suppl():41-4. PubMed ID: 21568008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals: 2nd multicenter study (GEIH-BLEE project, 2006)].
    Angel Díaz M; Ramón Hernández J; Martínez-Martínez L; Rodríguez-Baño J; Pascual A;
    Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):503-10. PubMed ID: 19329230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli.
    Bin C; Hui W; Renyuan Z; Yongzhong N; Xiuli X; Yingchun X; Yuanjue Z; Minjun C
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):351-7. PubMed ID: 16934430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum beta-lactamase.
    Peña C; Pujol M; Ardanuy C; Ricart A; Pallarés R; Liñares J; Ariza J; Gudiol F
    J Hosp Infect; 2001 Jan; 47(1):53-9. PubMed ID: 11161899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Wang SS; Lee NY; Hsueh PR; Huang WH; Tsui KC; Lee HC; Wu CJ; Chang CM; Huang CC; Huang CF; Ko WC
    J Microbiol Immunol Infect; 2011 Aug; 44(4):282-8. PubMed ID: 21524962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended-spectrum beta-lactamases and clinical outcomes: current data.
    Ramphal R; Ambrose PG
    Clin Infect Dis; 2006 Apr; 42 Suppl 4():S164-72. PubMed ID: 16544267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome.
    Gudiol C; Calatayud L; Garcia-Vidal C; Lora-Tamayo J; Cisnal M; Duarte R; Arnan M; Marin M; Carratalà J; Gudiol F
    J Antimicrob Chemother; 2010 Feb; 65(2):333-41. PubMed ID: 19959544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidemiology and risk factors for extended-spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon.
    Kanafani ZA; Mehio-Sibai A; Araj GF; Kanaan M; Kanj SS
    Am J Infect Control; 2005 Aug; 33(6):326-32. PubMed ID: 16061138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae isolated in a rural hospital.
    Basak S; Mallick SK; Bose S
    J Indian Med Assoc; 2009 Dec; 107(12):855-8. PubMed ID: 20509468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nosocomial bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae resistant to third-generation cephalosporins, Finland, 1999-2013: Trends, patient characteristics and mortality.
    Martelius T; Jalava J; Kärki T; Möttönen T; Ollgren J; Lyytikäinen O;
    Infect Dis (Lond); 2016; 48(3):229-34. PubMed ID: 26577519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.
    Kotapati S; Kuti JL; Nightingale CH; Nicolau DP
    J Infect; 2005 Oct; 51(3):211-7. PubMed ID: 16230218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiology of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp.: a nested case-control study from a tertiary hospital in London.
    Skippen I; Shemko M; Turton J; Kaufmann ME; Palmer C; Shetty N
    J Hosp Infect; 2006 Oct; 64(2):115-23. PubMed ID: 16859810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.